Ovarian cancer relapses within 95% of the year, Fudan tumor Wu Xiaohua team launches "China program"

(Health Times reporter Wang Guangzhao, Wen Wei) September 26, reporters from Fudan University Affiliated Oncology Hospital was informed that the hospital's oncology director Professor Wu Xiaohua team at the 2020 European Icoma Technology Association Conference, shared a "China program" on the treatment of recurring ovarian cancer PARP inhibitors.The
programme confirmed that patients with relapsed ovarian cancer who received the PARP inhibitor drug Nirapali maintenance had a 68 per cent reduced risk of disease progression or death, and that the patient's medium progression-free survival period reached 18.3 months, well ahead of the control group's 5.4-month data and more than three times longer. This means that the standardized maintenance treatment of ovarian cancer, which is more in line with national characteristics, will be "chaptered". As the first phase 3 clinical study of PARP inhibitors for native ovarian cancer, this achievement became the only Chinese women's tumor study to be selected for the full oral report of the General Assembly this year.
"Ovarian cancer is a 'silent tumor', the malignancy of the female reproductive system ranked first, more than 70% of patients at the time of initial diagnosis is already late," said Professor Wu Xiaohua, chairman of the gynaecological oncology committee of the China Anti-Cancer Association and a member of Fudan University's affiliated oncology hospital. Even with common treatments such as surgery and first-line chemotherapy, more than 90 percent of ovarian cancer patients will relapse within five years. "In particular, the proportion of all ovarian cancers with "platinum-sensitive recurrence" is about 50% to 70%, and the type relapses more than 6 months after undergoing combined chemotherapy with platinum.
and "PARP inhibitors" have been widely used in the treatment of many malignant tumors. Ovarian cancer treatment is one of the main applications of PARP inhibitors. Unfortunately, most of the research on the treatment of PARP inhibitors for ovarian cancer is concentrated in foreign medical centers, and the relevant research data of Chinese people are very scarce, especially the data of Phase 3 clinical studies are still blank.
To fill the research gap, Professor Wu Xiaohua led a team of researchers from more than 30 cancer hospitals across the country to launch China's first phase 3 randomized double-blind, placebo-controlled study of PARP inhibitors for ovarian cancer maintenance therapy in 2017. Over a period of 3 years, 265 patients with "platinum-sensitive recurrence of ovarian cancer" were included. The results showed that patients treated with the PARP inhibitor nirapali maintained had a 68 percent reduced risk of disease progression or death. Compared to the placebo group, nirapali treatment significantly extended the patient's medium progression-free survival. In addition, as of the study's release, 43 percent of patients in the Nirapali group were still receiving treatment, compared with 13 percent in the control group.
same time, the study is the world's first to design a starting dose suitable for Chinese, maximizing the balance between killing tumors and reducing adverse reactions in patients. Anemia, neutral granulocyte reduction and other adverse reactions significantly reduced. Wu Xiaohua said, "This study to further optimize the application of PARP inhibitors in ovarian cancer patients has a better help, is expected to change the past international treatment methods, under the guidance of individual precision medicine, to reduce adverse reactions in patients, should be considered as a global standard clinical practice for ovarian cancer maintenance treatment."
it is understood that, as China's largest cancer center for ovarian cancer patients, Fudan University Affiliated Cancer Hospital has more than 1100 annual ovarian cancer operations, accounting for 44.6% of the whole of Shanghai. According to data released by the hospital, the five-year survival rate of ovarian cancer patients treated by the hospital from 2008 to 2016 reached 49.7%, reaching the international advanced treatment level.
.